We have located links that may give you full text access.
Urine Specific Gravity as a Practical Marker for Identifying Suboptimal Fluid Intake of Runners ∼12-hr Postexercise.
International Journal of Sport Nutrition and Exercise Metabolism 2018 September 28
The legitimacy of urine specific gravity (USG) as a stand-alone measure to detect hydration status has recently been challenged. As an alternative to hydration status, the purpose of this study was to determine the diagnostic capability of using the traditional USG marker of >1.020 to detect insufficient recovery fluid consumption with consideration for moderate versus high sweat losses (2.00-2.99 or >3% body mass, respectively). Adequate recovery fluid intake was operationally defined as ≥100% beverage fluid intake plus food water from one or two meals and a snack. Runners (n = 59) provided 132 samples from five previous investigations in which USG was assessed 10-14 hr after 60-90 min runs in temperate-to-hot environments. Samples were collected after a meal (n = 58) and after waking (n = 74). When sweat losses exceeded 3% body mass (n = 60), the relationship between fluid replacement percentage and USG increased from r = -.55 to -.70. Correct diagnostic decision improved from 66.6 to 83.3%, and receiver operating characteristic area under the curve increased the diagnostic accuracy score from 0.76 to approaching excellent (0.86). Artifacts of significant prerun hyperhydration (eight of 15 samples has USG <1.005) may explain false positive diagnoses, while almost all (84%) cases of false positives were found when sweat losses were <3.0% of body mass. Evidence from this study suggests that euhydrated runners experiencing significant sweat losses who fail to reach adequate recovery fluid intake levels can be identified by USG irrespective of acute meal and fluid intake ∼12-hr postrun.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app